文献速递肝病

IL-17A/F通过上调PD-L1使胆管细胞限制T细胞驱动的实验性胆管炎

IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression.
PubMed 文献 · J Hepatol · 2020-11-13

该研究在小鼠胆管炎模型及人胆管类器官中探究抗原特异性CD8+ T细胞来源IL-17的作用。结果显示,IL-17A/F通过诱导胆管细胞PD-L1上调,限制CD8+ T细胞的细胞毒性和增殖,从而减轻胆管周围炎症;IL-17缺失或PD-L1阻断均加重胆管炎。

要点

  • IL-17A/F缺失的OT-1 CD8+ T细胞过继转移加重小鼠胆管周围炎症。
  • IL-17A/F通过上调胆管细胞PD-L1限制CD8+ T细胞增殖与细胞毒性。
  • 抗PD-L1抗体阻断或IL-17缺失均导致胆管炎加重。

核心结论

  • IL-17通过上调胆管细胞PD-L1在限制胆管炎和保护免受CD8+ T细胞介导的炎性胆管损伤中起重要作用。
  • 靶向IL-17治疗胆管炎时需谨慎。

研究设计与样本

  • 使用K14-OVAp小鼠在胆管细胞表达MHC I限制性OVA肽SIINFEKL,通过过继转移OT-1 CD8+ T细胞(OT-1wt或OT-1IL17ko)诱导胆管炎。
  • 体外评估小鼠和人胆管细胞/类器官对IL-17A的反应。

主要发现

  • 与转移OT-1wt T细胞相比,转移OT-1IL17ko细胞显著加重K14-OVAp受体小鼠的胆管周围炎症。
  • OT-1IL17ko T细胞在肝脏中高度活化,细胞毒性和增殖增加。
  • OT-1wt CD8+ T细胞产生的IL-17A/F诱导胆管细胞PD-L1上调,限制转移细胞的细胞毒性和增殖。
  • OT-1IL17ko T细胞未能诱导胆管细胞PD-L1,导致细胞毒性CD8+ T细胞失控扩增和胆管炎加重。
  • 转移OT-1wt T细胞后用抗PD-L1抗体阻断PD-L1也导致胆管炎加重。

临床怎么用

  • 在胆管炎治疗中靶向IL-17需谨慎,因IL-17可能通过PD-L1发挥保护作用。
  • PD-L1通路在限制CD8+ T细胞介导的胆管损伤中具有重要性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: IL-17A-producing T cells are present in autoimmune cholestatic liver diseases; however, little is known about the contribution of IL-17 to periductal immune responses. Herein, we investigated the role of IL-17 produced by antigen-specific CD8+ T cells in a mouse model of cholangitis and in vitro in human cholangiocyte organoids. METHODS: K14-OVAp mice express a major histocompatibility complex I-restricted ovalbumin (OVA) peptide sequence (SIINFEKL) on cholangiocytes. Cholangitis was induced by the adoptive transfer of transgenic OVA-specific ovalbumin transgene (OT)-1 CD8+ T cells that either had OT-1wt or lacked IL-17A/F (OT-1IL17ko). The response of mouse and human cholangiocytes/organoids to IL-17A was assessed in vitro. RESULTS: Transfer of OVA-specific OT-1IL17ko cells significantly aggravated periductal inflammation in K14-OVAp recipient mice compared with transfer of OT-1wt T cells. OT-1IL17ko T cells were highly activated in the liver and displayed increased cytotoxicity and proliferation. IL-17A/F produced by transferred OT-1wt CD8+ T cells induced upregulation of the inhibitory molecule programmed cell death ligand 1 (PD-L1) on cholangiocytes, restricting cholangitis by limiting cytotoxicity and proliferation of transferred cells. In contrast, OT-1IL17ko T cells failed to induce PD-L1 on cholangiocytes, resulting in uncontrolled expansion of cytotoxic CD8+ T cells and aggravated cholangitis. Blockade of PD-L1 after transfer of OT-1wt T cells with anti-PD-L1 antibody also resulted in aggravated cholangitis. Using human cholangiocyte organoids, we were able to confirm that IL-17A induces PD-L1 expression in cholangiocytes. CONCLUSIONS: We demonstrate that by upregulating PD-L1 on cholangiocytes, IL-17 has an important role in restricting cholangitis and protecting against CD8+ T cell-mediated inflammatory bile duct injury. Caution should be exercised when targeting IL-17 for the treatment of cholangitis. LAY SUMMARY: IL-17 is assumed to be a driver of inflammation in several autoimmune diseases, such as psoriasis. IL-17 is also present in inflammatory diseases of the bile duct, but its role in these conditions is not clear, as the effects of IL-17 depend on the context of its expression. Herein, we investigated the role of IL-17 in an experimental autoimmune cholangitis mouse model, and we identified an important protective effect of IL-17 on cholangiocytes, enabling them to downregulate bile duct inflammation via checkpoint inhibitor PD-L1.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Stein S, Henze L, Poch T, et al. IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression. J Hepatol. 2020. PMID: 33197512. doi:10.1016/j.jhep.2020.10.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。